# Ticagrelor

Drug · id `cardio:ticagrelor` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: BRILINTA

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Stroke  

## In plain language

Ticagrelor, sold as Brilinta, is an antiplatelet medicine of the P2Y12 inhibitor class. The FDA label lists three uses: making cardiovascular death, heart attack and stroke less likely in people with acute coronary syndrome or a past heart attack; making a first heart attack or stroke less likely in people with coronary artery disease at high risk; and making a stroke less likely after an acute ischemic stroke (NIH Stroke Scale score of 5 or less) or a high-risk transient ischemic attack. The label carries a boxed warning that, like other antiplatelet agents, it can cause significant, sometimes fatal bleeding.

## Technical summary

RxNorm ingredient 1116632; UNII GLH0314RVC; NDA022433, first approved on 2011-07-20 as a new molecular entity (Drugs@FDA record, sponsor ASTRAZENECA). The label read is the AstraZeneca label in openFDA (effective 2026-05-07); two repackager labels were not used. This page records label indications and the class only: no trial result is recorded for the medicine here, and no dose is given.

## Claims, with the population each applies to

## Context: United States approval record NDA022433 for Brilinta (ticagrelor)

Recipient: Recipient not specified; Population: Not stated in the fetched Drugs@FDA record. It names a product and a sponsor and gives no intended population or indication for the original approval.; Care setting: Not stated in the FDA record; Geography: United States (decision by the US Food and Drug Administration); Life stage: Not stated in the FDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)

### The openFDA Drugs@FDA record for New Drug Application NDA022433 (BRILINTA, ticagrelor tablets) lists the original approval as submission ORIG-1, with status date 20 July 2011, classified as Type 1 - New Molecular Entity, with standard review priority. The record names ASTRAZENECA as the sponsor of the application.

- Category: Regulatory
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: Not stated in the fetched Drugs@FDA record. It names a product and a sponsor and gives no intended population or indication for the original approval.; Care setting: Not stated in the FDA record; Geography: United States (decision by the US Food and Drug Administration); Life stage: Not stated in the FDA record; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (regulatory decision)
- Limitations: This claim records the original approval and the fields the record gives. The record fetched carries no indication text for the original approval, so the claim does not say what the medicine was approved to treat in 2011; current uses are in the label claim. The record also lists many later supplements. An approval is not a finding about how well the medicine works. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-10-30
- Sources:
  1. Supports: openFDA Drugs@FDA record for NDA022433 (BRILINTA, ticagrelor) (Regulator, edition openFDA Drugs@FDA application record returned on 2026-10-30. It lists the original approval as submission ORIG-1, with an approval status date of 20110720.) <https://api.fda.gov/drug/drugsfda.json?search=openfda.application_number:%22NDA022433%22&limit=1>
     Locator: results\[0\].application\_number. Retrieved 2026-10-30T19:21:09Z. Source state: Current. Version fingerprint: 90633381b9762b0a54d5085fe523d359574fce0d98600fe565a76aca35f8c991.
     How it applies: The application number of this record.
  2. Supports: openFDA Drugs@FDA record for NDA022433 (BRILINTA, ticagrelor) (Regulator, edition openFDA Drugs@FDA application record returned on 2026-10-30. It lists the original approval as submission ORIG-1, with an approval status date of 20110720.) <https://api.fda.gov/drug/drugsfda.json?search=openfda.application_number:%22NDA022433%22&limit=1>
     Locator: results\[0\].submissions\[14\].submission\_type. Retrieved 2026-10-30T19:21:09Z. Source state: Current. Version fingerprint: 90633381b9762b0a54d5085fe523d359574fce0d98600fe565a76aca35f8c991.
     How it applies: The original submission.
  3. Supports: openFDA Drugs@FDA record for NDA022433 (BRILINTA, ticagrelor) (Regulator, edition openFDA Drugs@FDA application record returned on 2026-10-30. It lists the original approval as submission ORIG-1, with an approval status date of 20110720.) <https://api.fda.gov/drug/drugsfda.json?search=openfda.application_number:%22NDA022433%22&limit=1>
     Locator: results\[0\].submissions\[14\].submission\_status\_date. Retrieved 2026-10-30T19:21:09Z. Source state: Current. Version fingerprint: 90633381b9762b0a54d5085fe523d359574fce0d98600fe565a76aca35f8c991.
     How it applies: The original approval status date, in compact form.
  4. Supports: openFDA Drugs@FDA record for NDA022433 (BRILINTA, ticagrelor) (Regulator, edition openFDA Drugs@FDA application record returned on 2026-10-30. It lists the original approval as submission ORIG-1, with an approval status date of 20110720.) <https://api.fda.gov/drug/drugsfda.json?search=openfda.application_number:%22NDA022433%22&limit=1>
     Locator: results\[0\].submissions\[14\].submission\_class\_code\_description. Retrieved 2026-10-30T19:21:09Z. Source state: Current. Version fingerprint: 90633381b9762b0a54d5085fe523d359574fce0d98600fe565a76aca35f8c991.
     How it applies: The submission classification of the original approval.
  5. Supports: openFDA Drugs@FDA record for NDA022433 (BRILINTA, ticagrelor) (Regulator, edition openFDA Drugs@FDA application record returned on 2026-10-30. It lists the original approval as submission ORIG-1, with an approval status date of 20110720.) <https://api.fda.gov/drug/drugsfda.json?search=openfda.application_number:%22NDA022433%22&limit=1>
     Locator: results\[0\].submissions\[14\].review\_priority. Retrieved 2026-10-30T19:21:09Z. Source state: Current. Version fingerprint: 90633381b9762b0a54d5085fe523d359574fce0d98600fe565a76aca35f8c991.
     How it applies: The review priority of the original approval.
  6. Supports: openFDA Drugs@FDA record for NDA022433 (BRILINTA, ticagrelor) (Regulator, edition openFDA Drugs@FDA application record returned on 2026-10-30. It lists the original approval as submission ORIG-1, with an approval status date of 20110720.) <https://api.fda.gov/drug/drugsfda.json?search=openfda.application_number:%22NDA022433%22&limit=1>
     Locator: results\[0\].sponsor\_name. Retrieved 2026-10-30T19:21:09Z. Source state: Current. Version fingerprint: 90633381b9762b0a54d5085fe523d359574fce0d98600fe565a76aca35f8c991.
     How it applies: The application sponsor, as the record writes the name.

## Context: People for whom the US label of ticagrelor (Brilinta) lists an indication: acute coronary syndrome or past heart attack, high-risk coronary artery disease, acute ischemic stroke or high-risk transient ischemic attack

Recipient: Adult; Population: Patients described in the indications section of the label. The label does not state an age range in the passages read.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Follow-up: Not applicable (label statement)

### The US label of BRILINTA (ticagrelor), in the AstraZeneca version dated 7 May 2026 in openFDA, lists the medicine for lowering the chance of cardiovascular death, myocardial infarction and stroke in patients with acute coronary syndrome or a history of myocardial infarction. It also lists it for lowering the chance of a first myocardial infarction or stroke in patients with coronary artery disease at high risk for such events, and for lowering the chance of stroke in patients with acute ischemic stroke (NIH Stroke Scale score of 5 or less) or a high-risk transient ischemic attack. The label carries a boxed warning that, like other antiplatelet agents, the medicine can cause significant, sometimes fatal bleeding.

- Category: Description
- Evidence stage: Evidence stage not applicable
- Certainty: Certainty not assessed
- Applies to: Recipient: Adult; Population: Patients described in the indications section of the label. The label does not state an age range in the passages read.; Care setting: Prescription medicine, as described in the US label; Geography: United States (label of the US Food and Drug Administration); Life stage: Not stated in the label passages read; Follow-up: Not applicable (label statement)
- Limitations: This claim records what the label says it is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. Only the indications and the first line of the boxed warning were read; contraindications, doses, interactions and other warnings were not recorded. Labels change: openFDA also lists repackager copies with older text. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked: 2026-10-30
- Sources:
  1. Supports: openFDA drug label record for BRILINTA (ticagrelor tablets), AstraZeneca label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id f7b3f443-e83d-4bf2-0e96-023448fed9a8 (manufacturer AstraZeneca Pharmaceuticals LP), returned on 2026-10-30, from a dataset last updated 2026-10-30. The label text is dated 2026-05-07 (effective\_time). Two other openFDA records of BRILINTA labels from repackagers (Aphena Pharma Solutions, 2024-04-08; Cardinal Health 107, 2026-04-14) were listed and not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22f7b3f443-e83d-4bf2-0e96-023448fed9a8%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.1, sentence 1, fragment 1 of 2. Retrieved 2026-10-30T19:22:03Z. Source state: Current. Version fingerprint: c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b.
     How it applies: First indication, first part.
  2. Supports: openFDA drug label record for BRILINTA (ticagrelor tablets), AstraZeneca label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id f7b3f443-e83d-4bf2-0e96-023448fed9a8 (manufacturer AstraZeneca Pharmaceuticals LP), returned on 2026-10-30, from a dataset last updated 2026-10-30. The label text is dated 2026-05-07 (effective\_time). Two other openFDA records of BRILINTA labels from repackagers (Aphena Pharma Solutions, 2024-04-08; Cardinal Health 107, 2026-04-14) were listed and not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22f7b3f443-e83d-4bf2-0e96-023448fed9a8%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.1, sentence 1, fragment 2 of 2. Retrieved 2026-10-30T19:22:03Z. Source state: Current. Version fingerprint: c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b.
     How it applies: First indication, second part.
  3. Supports: openFDA drug label record for BRILINTA (ticagrelor tablets), AstraZeneca label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id f7b3f443-e83d-4bf2-0e96-023448fed9a8 (manufacturer AstraZeneca Pharmaceuticals LP), returned on 2026-10-30, from a dataset last updated 2026-10-30. The label text is dated 2026-05-07 (effective\_time). Two other openFDA records of BRILINTA labels from repackagers (Aphena Pharma Solutions, 2024-04-08; Cardinal Health 107, 2026-04-14) were listed and not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22f7b3f443-e83d-4bf2-0e96-023448fed9a8%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.2, sentence 1, fragment 1 of 2. Retrieved 2026-10-30T19:22:03Z. Source state: Current. Version fingerprint: c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b.
     How it applies: Second indication, first part.
  4. Supports: openFDA drug label record for BRILINTA (ticagrelor tablets), AstraZeneca label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id f7b3f443-e83d-4bf2-0e96-023448fed9a8 (manufacturer AstraZeneca Pharmaceuticals LP), returned on 2026-10-30, from a dataset last updated 2026-10-30. The label text is dated 2026-05-07 (effective\_time). Two other openFDA records of BRILINTA labels from repackagers (Aphena Pharma Solutions, 2024-04-08; Cardinal Health 107, 2026-04-14) were listed and not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22f7b3f443-e83d-4bf2-0e96-023448fed9a8%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.2, sentence 1, fragment 2 of 2. Retrieved 2026-10-30T19:22:03Z. Source state: Current. Version fingerprint: c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b.
     How it applies: Second indication, second part.
  5. Supports: openFDA drug label record for BRILINTA (ticagrelor tablets), AstraZeneca label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id f7b3f443-e83d-4bf2-0e96-023448fed9a8 (manufacturer AstraZeneca Pharmaceuticals LP), returned on 2026-10-30, from a dataset last updated 2026-10-30. The label text is dated 2026-05-07 (effective\_time). Two other openFDA records of BRILINTA labels from repackagers (Aphena Pharma Solutions, 2024-04-08; Cardinal Health 107, 2026-04-14) were listed and not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22f7b3f443-e83d-4bf2-0e96-023448fed9a8%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.3, sentence 1, fragment 1 of 2. Retrieved 2026-10-30T19:22:03Z. Source state: Current. Version fingerprint: c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b.
     How it applies: Third indication, first part.
  6. Supports: openFDA drug label record for BRILINTA (ticagrelor tablets), AstraZeneca label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id f7b3f443-e83d-4bf2-0e96-023448fed9a8 (manufacturer AstraZeneca Pharmaceuticals LP), returned on 2026-10-30, from a dataset last updated 2026-10-30. The label text is dated 2026-05-07 (effective\_time). Two other openFDA records of BRILINTA labels from repackagers (Aphena Pharma Solutions, 2024-04-08; Cardinal Health 107, 2026-04-14) were listed and not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22f7b3f443-e83d-4bf2-0e96-023448fed9a8%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.3, sentence 1, fragment 2 of 2. Retrieved 2026-10-30T19:22:03Z. Source state: Current. Version fingerprint: c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b.
     How it applies: Third indication, second part.
  7. Supports: openFDA drug label record for BRILINTA (ticagrelor tablets), AstraZeneca label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id f7b3f443-e83d-4bf2-0e96-023448fed9a8 (manufacturer AstraZeneca Pharmaceuticals LP), returned on 2026-10-30, from a dataset last updated 2026-10-30. The label text is dated 2026-05-07 (effective\_time). Two other openFDA records of BRILINTA labels from repackagers (Aphena Pharma Solutions, 2024-04-08; Cardinal Health 107, 2026-04-14) were listed and not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22f7b3f443-e83d-4bf2-0e96-023448fed9a8%22&limit=1>
     Locator: results\[0\].indications\_and\_usage\[0\], 1.3, parenthetical. Retrieved 2026-10-30T19:22:03Z. Source state: Current. Version fingerprint: c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b.
     How it applies: The stroke severity limit the label gives for the third indication.
  8. Supports: openFDA drug label record for BRILINTA (ticagrelor tablets), AstraZeneca label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id f7b3f443-e83d-4bf2-0e96-023448fed9a8 (manufacturer AstraZeneca Pharmaceuticals LP), returned on 2026-10-30, from a dataset last updated 2026-10-30. The label text is dated 2026-05-07 (effective\_time). Two other openFDA records of BRILINTA labels from repackagers (Aphena Pharma Solutions, 2024-04-08; Cardinal Health 107, 2026-04-14) were listed and not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22f7b3f443-e83d-4bf2-0e96-023448fed9a8%22&limit=1>
     Locator: results\[0\].boxed\_warning\[0\], sentence 1. Retrieved 2026-10-30T19:22:03Z. Source state: Current. Version fingerprint: c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b.
     How it applies: First line of the boxed warning.
  9. Background: openFDA drug label record for BRILINTA (ticagrelor tablets), AstraZeneca label: indications, mechanism and boxed warning (Regulator, edition The openFDA drug label record for set id f7b3f443-e83d-4bf2-0e96-023448fed9a8 (manufacturer AstraZeneca Pharmaceuticals LP), returned on 2026-10-30, from a dataset last updated 2026-10-30. The label text is dated 2026-05-07 (effective\_time). Two other openFDA records of BRILINTA labels from repackagers (Aphena Pharma Solutions, 2024-04-08; Cardinal Health 107, 2026-04-14) were listed and not used.) <https://api.fda.gov/drug/label.json?search=set_id:%22f7b3f443-e83d-4bf2-0e96-023448fed9a8%22&limit=1>
     Locator: results\[0\].effective\_time. Retrieved 2026-10-30T19:22:03Z. Source state: Current. Version fingerprint: c8cdfae111fb290796821eb12768a9c715675322a98a327ffd5bb3cc07fef64b.
     How it applies: Effective date of the label text read, 20260507.

## Connected pages

- Ticagrelor is a P2Y12 inhibitor (FDA established pharmacologic class in RxClass): P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)
- FDA label lists acute coronary syndrome or a past heart attack as an indication: Acute coronary syndrome (`cardio:acute-coronary-syndrome`) [a claim, not a settled fact; see claim `cardio:claim-fda-ticagrelor-label-indications` and its context]
- Files under this front: Medicines (`cardio:front-medicines`)

## Registry records

Records a program assembled from a public registry; no person wrote or checked them. They are counted here, not listed: the JSON record of this page lists each one in its relationships.

- 1 registry product
- 70 registry trials

## Provenance

Content hash: 2d701f022832635cbab9f6e13c1c8e7dcc966ad31e8a1ecaeee1649df4f09f8d
Last substantive edit: 2026-10-30
Evidence last checked: 2026-10-30
